Peter Menziuso Named EVP and President, BD Interventional

Peter Menziuso Named EVP and President, BD Interventional

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a $5 billion global business with responsibility for commercial operations, R&D, supply chain, quality, finance and medical affairs.

Throughout his career, Menziuso has been recognized for strengthening market leadership, building high‑performing teams and translating strategy into sustained performance through commercial rigor and operational excellence. His global leadership experience, coupled with his customer obsession and ability to lead at scale position him well to accelerate execution and deliver continued growth for BD Interventional.

"BD Interventional has a strong track record of performance, and Peter is the right leader to build on that momentum and continue delivering results," said Tom Polen, chairman, CEO and president of BD. "Peter brings a strong combination of strategic leadership and operational discipline. He is grounded in delivering for customers and patients, building strong teams and driving consistent performance, positioning the business for sustained growth and continued strength across the portfolio."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X  @BDandCo or Instagram @becton_dickinson.

Contacts:


Media

Investors

Megan Dubrowski
Senior Director, Executive Communications
Megan.Dubrowski@bd.com  

Shawn Bevec

SVP, Investor Relations

Investor_Relations@bd.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/peter-menziuso-named-evp-and-president-bd-interventional-302774280.html

SOURCE BD (Becton, Dickinson and Company)

News Provided by PR Newswire via QuoteMedia

BDX
The Conversation (0)
Red Mountain Mining

Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter

Red Mountain Mining Limited (ASX: RMX, US CODE: RMXFF, or “Company”), a Critical Minerals exploration and development company with an established portfolio in Tier-1 Mining Districts in the United States and Australia, is pleased to announce the Company’s newly-acquired Thompson Falls Antimony... Keep Reading...
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus™. This first-in-class blood test is available from Thursday, 27 March... Keep Reading...
Bcal Diagnostics Limited

BCAL Commences US Operations

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”) is pleased to announce that it has established a North Carolina, United States of America, incorporated wholly owned subsidiary, BCAL Diagnostics, Inc. (“BCAL US”) which will commence operations on 2 September 2024.... Keep Reading...
TSXV:SYH

Skyharbour Signs Option Agreement with Black Shield Metals Corp to Option 75% of the Mann Lake Uranium Project

Skyharbour Resources Ltd. (TSX-V: SYH ) (OTCQB: SYHBF ) (Frankfurt: SC1P ) ("Skyharbour" or the "Company") is pleased to announce that it has entered into an option agreement (the "Option Agreement") with Black Shield Metals Corp. (CSE: BDX) ("Black Shield") which provides Black Shield an... Keep Reading...
vegn stock cse

CSE Reports April 2021 Market Statistics

CSE is increasingly the exchange of choice for successful entrepreneursThe Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of April 2021. Trading volume exceeded three billion shares, while the total capital raised by issuers exceeded $1... Keep Reading...

Interactive Chart

Latest Press Releases

Related News